GleamWall
中文EN

RTSN Retension Pharmaceuticals, Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 2002988 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY—
TTM EPS YoY—
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE—
ROA—
ROIC (approx.)—
Asset turnover—

Leverage & solvency

Liabilities / assets47.1%
Debt / equity—
Current ratio2.12x
Interest coverage—

Cash quality & payout

Operating cash flow / net income—
Accruals ratio—
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q32025-09-302025Q22025-06-302025Q12025-03-31
Income statement
Revenue——————
R&D expense$5.02M——$1.37M——
SG&A expense$990,759——$299,574——
Operating income-$6.01M——-$1.66M——
Net income-$5.92M-$4.14M-$3.38M-$1.48M-$1.23M-$656,497
EPS (basic)-7.33——-1.83——
EPS (diluted)-7.33——-1.83——
Weighted avg. shares (diluted)807,894——805,154——
Balance sheet
Cash & equivalents$9.19M——$19.42M——
Current assets$14.15M—————
Total assets$14.15M—————
Current liabilities$6.66M—————
Total liabilities$6.66M—————
Shareholders' equity-$20.66M-$14.92M-$10.93M-$4.99M-$3.55M-$2.35M
Shares outstanding807,928—————
Cash flow statement
Operating cash flow——————

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.